Advancing novel therapies from promising ideas to marketable products

Melbourne Laboratories™ LLC is a newly-created company specializing in the development of novel pharmaceutical products across a wide spectrum of therapeutic classes. The three founding members of Melbourne have deep experience in a wide variety of practice areas, including FDA regulatory requirements, clinical development, manufacturing, API sourcing and commercialization.

Melbourne’s President and Chief Scientific Officer is Robert (Bob) W. Pollock. Bob is a registered pharmacist who served as a commissioned officer in the Public Health Service. Bob spent a number of years at FDA in various positions, his last assignment being Acting Deputy Director, Office of Generic Drugs. For the past 20 years, Bob has been with Lachman Consultant Services, the premier regulatory consulting firm in the pharmaceutical industry. He attained the title of Executive Vice President in 2009, retired from Lachman at the end of 2012, and now serves as Senior Advisor and Outside Director to the Board. While in his new position with Melbourne, Bob will continue his association with Lachman in that capacity.

Melbourne is currently advancing a number of projects that will be available for licensing in the next few years. The Company is also interested in partnering with individuals and companies who might have projects that could benefit from Melbourne’s expertise.

Contact Melbourne at